IRIS
GALLUZZO, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.889
EU - Europa 781
AS - Asia 252
Continente sconosciuto - Info sul continente non disponibili 5
SA - Sud America 5
OC - Oceania 4
AF - Africa 1
Totale 11.937
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.886
IE - Irlanda 243
IT - Italia 171
CN - Cina 151
DE - Germania 81
UA - Ucraina 69
FR - Francia 50
GB - Regno Unito 49
SE - Svezia 37
KR - Corea 30
IN - India 21
PL - Polonia 16
FI - Finlandia 14
RU - Federazione Russa 13
SG - Singapore 11
ES - Italia 8
KG - Kirghizistan 7
CH - Svizzera 6
JP - Giappone 6
MY - Malesia 6
NL - Olanda 6
BE - Belgio 5
TR - Turchia 5
AU - Australia 4
CA - Canada 3
CL - Cile 3
EU - Europa 3
GR - Grecia 3
RO - Romania 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AT - Austria 2
BD - Bangladesh 2
BR - Brasile 2
DK - Danimarca 2
HK - Hong Kong 2
IR - Iran 2
SI - Slovenia 2
UZ - Uzbekistan 2
IL - Israele 1
KZ - Kazakistan 1
MA - Marocco 1
MN - Mongolia 1
NO - Norvegia 1
TH - Thailandia 1
Totale 11.937
Salva come PNG Salva come JPEG
Città #
Wilmington 3.189
Houston 2.938
Woodbridge 1.609
Fairfield 705
Ashburn 436
Chandler 340
Seattle 338
Cambridge 260
Dublin 224
Ann Arbor 205
Medford 166
Dearborn 93
Beijing 83
Lawrence 79
San Diego 55
Rome 48
Jacksonville 43
Zhengzhou 20
Menlo Park 18
London 17
Redwood City 17
Seoul 17
New York 15
Perugia 15
Esslingen am Neckar 13
Falls Church 13
Kraków 13
Pune 11
Saint Petersburg 9
Shanghai 9
Milan 8
Engelhard 7
Kilburn 7
Norwalk 7
Mountain View 6
Brussels 5
Nanchang 5
Nanjing 5
Putrajaya 5
Bologna 4
Guangzhou 4
Islington 4
Madrid 4
Nuremberg 4
Renton 4
Sedico 4
Chengdu 3
Chicago 3
Coushatta 3
Detroit 3
Hefei 3
Helsinki 3
Hyderabad 3
Iesi 3
Jinan 3
Lausanne 3
St. George 3
Warsaw 3
Washington 3
Wuhan 3
Ōtsu 3
Aprilia 2
Bari 2
Chions 2
Clearwater 2
Del Norte 2
Frosinone 2
Hong Kong 2
Jinhua 2
Los Angeles 2
Melbourne 2
Monte Vista 2
Mumbai 2
Nanning 2
Palo Alto 2
Phoenix 2
Piombino Dese 2
San Jose 2
Sesto San Giovanni 2
Taranto 2
Toronto 2
Verona 2
Acton 1
Albino 1
Amsterdam 1
Ankara 1
Antalya 1
Apeldoorn 1
Ardabil 1
Astana 1
Athens 1
Auburn 1
Augusta 1
Bakersfield 1
Bangkok 1
Baotou 1
Bengaluru 1
Bergisch Gladbach 1
Billings 1
Cassano Magnago 1
Totale 11.186
Salva come PNG Salva come JPEG
Nome #
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients. 418
Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis 383
HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. 370
Tildrakizumab for treating psoriasis 365
Brodalumab for the treatment of psoriasis 360
Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections 360
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice 353
Role of HLA- C*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients. 353
Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients 344
Tofacitinib for the treatment of psoriasis 343
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation 341
The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature 338
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 325
New insight into the pathogenesis of nail psoriasis and overview of treatment strategies 322
A safety evaluation of guselkumab for the treatment of psoriasis 303
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. 293
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. 289
A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab 281
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 267
Photo-recall cutaneous reaction to gemcitabine 264
Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy 264
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature 263
Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab 260
High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab 245
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date 236
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial 234
Pharmacotherapeutic management of psoriasis in adolescents and children 220
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study 216
Successful treatment of psoriatic crumbly nails with ustekinumab 207
Therapeutic monitoring of male genital lichen sclerosus: usefulness of reflectance confocal microscopy 200
The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis 199
Skin immunity and its dysregulation in psoriasis 199
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 191
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience 185
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis 157
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo 154
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature 144
Real life experience of apremilast in psoriasis and arthritis psoriatic patients: preliminary results on metabolic biomarkers 144
Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab 124
Genetic variations in IL6 and IL12B decreasing the risk for psoriasis 98
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab 94
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis 93
A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab 76
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris 65
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases 64
Italian guidelines in diagnosis and treatment of alopecia areata 64
Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis 62
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study 62
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions? 61
Assessment of HLA Cw6 genotype and correlation to ustekinumab response in a large cohort of patients with moderate-to-severe psoriasis 60
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 59
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era 59
Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study 54
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis 53
Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information 52
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up 48
Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in psoriasis 48
Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis 42
Linear psoriasis following the typical distribution of the sciatic nerve 40
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome 40
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study 40
Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies 40
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts 39
HLACw6 predisposes to clinical response to IL12/23 blocker ustekinumab: Results of short- and long-term treatment in anti-TNF naïve patients 38
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis 36
Human leucocyte antigen Cw6 predisposes to clinical response to the inlterleukin-12/23 blocker ustekinumab: results of long-term treatment 36
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year 29
Genetic variati ons in IL6 and IL12B as protecti ve markers for psoriasis Abstracts of the 2013 International Investigative Dermatology Meeting. May 8-11, 2013. Edinburgh, Scotland, United Kingdom 27
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study 27
Diagnosis and management of cutaneous and anogenital lichen sclerosus: Recommendations from the Italian Society of Dermatology (SIDemaSt) 26
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis 25
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 25
Genetic variations in IL6 and IL12B as protective markers for psoriasis 23
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations 19
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy 18
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 17
Potential role of HLA-Cw6 in clinical response to anti-tumour necrosis factor alpha and t-cell targeting agents in psoriasis patients 17
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents 17
HLA-C*06:02 allele can influence clinical efficacy of certolizumab pegol? 17
The value of genotyping patients for the presence of HLA-C in the personalized treatment of psoriasis 17
A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients 16
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry 16
Quality of life and psychological impact in patients with atopic dermatitis 16
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study 15
Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks 12
letter in response to the case report: “recalcitrant generalized granuloma annulare treated successfully with dupilumab” 9
successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: a case series 8
Successful long‐term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series 6
Allelic Variants of HLA-C Upstream Region, PSORS1C3, MICA, TNFA and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with Psoriasis 6
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study) 4
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement 4
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks 4
Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study 3
Totale 12.460
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.377
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.377
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019843 0 0 0 0 0 0 0 0 0 219 283 341
2019/20204.020 266 251 212 336 367 404 346 349 484 438 311 256
2020/20213.113 313 311 310 329 407 431 351 317 65 166 80 33
2021/2022908 47 72 81 18 33 39 141 35 67 56 73 246
2022/2023894 111 87 76 71 58 228 73 42 69 22 30 27
2023/2024409 34 7 16 16 48 91 94 60 3 40 0 0
Totale 12.460